enGene Holdings Inc. (ENGNW)

Market Cap	581.12M
Revenue (ttm)	n/a
Net Income (ttm)	-94.72M
Shares Out	51.19M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	645
Open	2.880
Previous Close	2.705
Day's Range	2.870 - 2.900
52-Week Range	0.510 - 3.800
Beta	-0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 19, 2025

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Ronald H. Cooper
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGNW
• Website: https://www.engene.com